Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives.
Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives.
复制标题
卵巢的清晰细胞癌：分子见解和未来的治疗观点。
DOI：
10.3802/jgo.2016.27.e31
复制
发表时间：
2016-05
影响因子：
3.9
通讯作者：
Kimura T
中科院分区：
文献类型：
--
作者：
Mabuchi S;Sugiyama T;Kimura T
已知卵巢透明细胞癌（CCC）对化疗药物的敏感性较差，并且与更常见的浆液性腺癌或子宫内膜样腺癌相比预后较差。为了提高卵巢CCC患者的生存率，需要更深入地了解CCC癌变机制，并努力在一线治疗和复发性疾病的挽救治疗中开发新的治疗策略。在本次演讲中，我们首先总结了致癌机制。然后，我们重点介绍了卵巢 CCC 的有前景的治疗靶点，并提供了有关抑制这些分子靶点的新型药物的信息。此外，我们还讨论了最适合与靶向药物联合治疗卵巢 CCC 的细胞毒性抗癌药物。
Clear cell carcinoma (CCC) of the ovary is known to show poorer sensitivity to chemotherapeutic agents and to be associated with a worse prognosis than the more common serous adenocarcinoma or endometrioid adenocarcinoma. To improve the survival of patients with ovarian CCC, the deeper understanding of the mechanism of CCC carcinogenesis as well as the efforts to develop novel treatment strategies in the setting of both front-line treatment and salvage treatment for recurrent disease are needed. In this presentation, we first summarize the mechanism responsible for carcinogenesis. Then, we highlight the promising therapeutic targets in ovarian CCC and provide information on the novel agents which inhibit these molecular targets. Moreover, we discuss on the cytotoxic anti-cancer agents that can be best combined with targeted agents in the treatment of ovarian CCC.